Lisata Therapeutics Inc. (LSTA)
| Bid | 2.02 |
| Market Cap | 19.65M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -19.98M |
| EPS (ttm) | -2.4 |
| PE Ratio (ttm) | -0.95 |
| Forward PE | -2.35 |
| Analyst | Buy |
| Ask | 2.45 |
| Volume | 26,858 |
| Avg. Volume (20D) | 25,603 |
| Open | 2.09 |
| Previous Close | 2.17 |
| Day's Range | 2.13 - 2.33 |
| 52-Week Range | 1.87 - 4.20 |
| Beta | 1.00 |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfun...
Analyst Forecast
According to 1 analyst ratings, the average rating for LSTA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 557.89% from the latest price.
Stock Forecasts
2 days ago · proactiveinvestors.com
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMILisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors tha...
1 month ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMILisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company's strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Maz...
1 month ago · proactiveinvestors.com
Lisata Therapeutics partners with GATC Health to advance AI-driven drug developmentLisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading drug discovery firm leveraging artificial intelligence. The...
1 month ago · seekingalpha.com
Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call TranscriptLisata Therapeutics, Inc. (NASDAQ:LSTA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants John Menditto - Vice President of Investor Relations and Corporate Communica...
1 month ago · proactiveinvestors.com
Lisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progressLisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMILisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCE...
2 months ago · proactiveinvestors.com
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trialLisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in com...
3 months ago · proactiveinvestors.com
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trialLisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is ...